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Background: The aim of this study was to analyse the risk of uncomplicated peptic ulcer disease (PUD) in a cohort
of new users of low-dose acetylsalicylic acid (ASA) for secondary prevention of cardiovascular events in a UK primary
care setting.
Methods: New users of low-dose ASA for secondary prevention of cardiovascular events, aged 50-84 years in 2000-2007,
were identified from The Health Improvement Network. Among those 38,975 individuals, 309 patients were considered to
be incident cases of uncomplicated PUD. Incidence of uncomplicated PUD was calculated and a nested case–control
analysis adjusted for potential confounding factors was performed to calculate the odds ratios (ORs) for the association of
potential risk factors with uncomplicated PUD.
Results: The crude incidence of uncomplicated PUD was 1.41 per 1000 person-years (95% confidence interval [CI],
1.26-1.58). Individuals with a history of PUD were more likely to develop uncomplicated PUD than those without such a
history (hazard ratio [HR], 2.22, 95% CI, 1.60-3.09). In nested case–control analyses, the risk of uncomplicated PUD was
associated with current use of non-steroidal anti-inflammatory drugs, oral steroids or acid suppressants. Other risk factors
for developing uncomplicated PUD included smoking, stress, depression, anaemia and social deprivation.
Conclusion: Our results indicate that several risk factors significantly increase the risk of development of uncomplicated
PUD in new users of low-dose ASA. Therefore, physicians should monitor ASA users for gastrointestinal symptoms and
signs of ulcer, particularly if they have additional risk factors.
Keywords: Acetylsalicylic acid, Nested case–control study, Uncomplicated peptic ulcer diseaseBackground
Current evidence-based guidelines recommend the long-
term use of acetylsalicylic acid (ASA) for the secondary
prevention of cardiovascular events [1,2]. Use of ASA
has, however, been shown to increase the risk of gastro-
intestinal complications, including upper gastrointestinal
bleeding [3] and uncomplicated peptic ulcer disease
(PUD) [4]. Upper gastrointestinal symptoms have been
shown to affect patients’ health-related quality of life [5]
and may lead to discontinuation of ASA therapy [6-9],* Correspondence: lagarcia@ceife.es
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unless otherwise stated.leaving patients at elevated risk of cardiovascular events
[10-12]. Moreover, uncomplicated PUD symptoms may
influence the prescribing behaviour of primary care phy-
sicians (PCPs). It is therefore important to understand
the additional factors associated with an increased risk
of PUD in patients using ASA for the secondary preven-
tion of cardiovascular events.
Although these additional risk factors have been stud-
ied for complicated PUD [3], data remain scarce for un-
complicated PUD. Uncomplicated PUD contributes to
the overall health burden of PUD and may lead to com-
plications in some patients [13,14]; even in the absence
of overt bleeding, uncomplicated PUD may cause an-
aemia [15]. In a previous observational study in the UKral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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complicated PUD was 0.75 cases per 1000 person-years in
the general UK population [16]. A similar incidence of un-
complicated PUD was also reported in a population-based
study in Denmark [13].
The aims of the present study were to estimate the in-
cidence of symptomatic uncomplicated PUD among a
cohort of individuals starting low-dose ASA therapy for
the secondary prevention of cardiovascular events in a
UK primary care setting and to determine the main fac-
tors associated with an increased risk of uncomplicated
PUD in a nested case–control analysis.
Methods
Data source
A retrospective cohort study was performed using data
from The Health Improvement Network (THIN), a com-
puterized primary care database containing anonymized
records for individuals currently registered with participat-
ing primary care practices in the UK. THIN is age, sex and
geographically representative of the UK population [17]
and has been extensively validated for use in epidemio-
logical studies [18]. Data recorded in THIN include patient
demographics, details of consultations with PCPs, informa-
tion about consultant referrals and hospitalizations, labora-
tory test results, diagnoses and prescriptions. The Read
classification is used to code specific diagnoses [19,20], and
a drug dictionary based on data from the Gemscript classi-
fication is used to record prescriptions [21]. Ethical ap-
proval for the collection of data in THIN database was
obtained from a Multicentre Research Ethics Committee
(NHS; MREC reference number: 08/H0305/49).
Study cohort
A previously identified cohort of patients who received a
first-ever prescription for low-dose ASA (75-300 mg/day)
for secondary prevention of cardiovascular ischaemic dis-
eases or cerebrovascular ischaemic events and who were
aged 50-84 years between 1 January 2000 and 31 December
2007 was used for the present study [11]. Patients were
required to have been registered for at least 2 years with
their PCP, and to have at least 1 year of computerized pre-
scription history. The date of their first-ever recorded pre-
scription for low-dose ASA for secondary prevention of
cardiovascular events was defined as their start date. All
patients who had a prescription for low-dose ASA re-
corded before their start date were excluded, as were pa-
tients with a recorded diagnosis of alcohol abuse or cancer.
Individuals aged 70 years or older with a follow-up longer
than 1 year and less than two health contacts during their
follow-up period were also excluded (proxy for incomplete
data recording). The total study cohort consisted of 38,975
individuals, who were followed up to identify incident cases
of uncomplicated PUD.Uncomplicated PUD case ascertainment
All study cohort members were followed up for a mean
of 5.6 years from the first day after their start date to the
earliest of the following endpoints: first recorded diagno-
sis of uncomplicated PUD, cancer, alcohol abuse or
alcohol-related disease; reaching the age of 85 years; date
of the last practice data collection; death; or end of the
study period (30 September 2011).
We identified 555 patients with a first computer-
recorded Read code suggesting uncomplicated PUD
during follow-up. For all of them, we requested free-text
comments close to the date of the Read code (a week
before and a month after that date) and comments as-
sociated with upper gastrointestinal-related diagnoses re-
corded any time before and up to 6 months after the
computer-detected uncomplicated PUD diagnosis. After
removal of personal identifiers and information on drug
use, we manually reviewed the profiles of these 555 pa-
tients. Individuals were considered to have uncomplicated
PUD if a clinical diagnosis had been made during a spe-
cialist visit or hospitalization, and if the site of the ulcer
was located in the stomach or duodenum without any
major complication, bleeding or perforation. Following
this review, 327 patients were classified as definite uncom-
plicated PUD cases, 20 as possible cases (insufficient infor-
mation for ascertainment) and 208 as non-cases. Among
the 327 definite uncomplicated PUD cases, almost 90% of
records showed that an endoscopy had been performed. A
little over half of definite cases of uncomplicated PUD had
a Helicobacter pylori test recorded on or near the date of
diagnosis (n = 179, 54.7%).
To confirm the validity of our case ascertainment fur-
ther, we sent a questionnaire to the corresponding PCPs
requesting confirmation and copies of paper-based records
for 100 patients randomly sampled from the definite cases
(n = 96) and possible cases (n = 4). We received records
for 98 patients. The uncomplicated PUD diagnosis was
confirmed by the PCPs for 76 patients. The confirmation
rate among the definite cases was 80% and only 25%
among possible cases. We retained as cases all definite
cases confirmed by a questionnaire (n = 75) and those
definite cases for which we did not have a questionnaire
(n = 233). Due to the low confirmation rate among pos-
sible cases, we only retained the single patient initially
classified as possible, whose diagnosis was confirmed by
the PCP. The majority of patients who were not retained
as uncomplicated PUD cases had a discharge letter with a
diagnosis of a complication (e.g. bleeding) not recorded in
their computerized file.
Following this two-step review process, 309 patients
were considered to be incident cases of uncomplicated
PUD: 308 individuals from those initially classified as def-
inite and 1 from the possible cases (Figure 1). The index









Incident cases of uncomplicated PUD
N = 309
Gastric n = 188
Duodenal n = 103
Multiple sites n = 18
Non-cases
N = 246
GI bleeding or perforation n = 184
Not confirmed n = 23
Past event n = 14
Cancer n = 8
Alcoholism n = 1
Possible after free-text review but 





Death n = 4765
Age n = 5278
Alcohol n = 621
Cancer n = 4448
Figure 1 Study design and case ascertainment. Abbreviations: GI-Gastrointestinal; PUD-Peptic ulcer disease.
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ing to the diagnosis of PUD (n = 165), whichever occurred
first. When the date of the first symptom was used as the
index date, the mean time to the computer-recorded diag-
nosis of uncomplicated PUD was 35 days. The peptic ulcer
was located in the stomach for 188 patients (61%), the
duodenum for 103 (33%) and multiple sites (stomach and
duodenum) for 18 (6%).
Selection of controls
A date within the study period was generated at random
for each member of the study cohort, excluding PUD
cases. If the random date was included in the individual’s
person-time contribution, we marked that person as an eli-
gible control. The random date for each control individual
was used as the index date in the nested case–control ana-
lysis. In total, 2000 controls, frequency-matched to cases
by age (within 1 year), sex and follow-up time (interval be-
tween start date and index date), were randomly selected
from the pool of eligible controls.
Risk factor ascertainment
Information on patient demographics, baseline character-
istics, comorbidities and comedications was collected from
THIN. In the cohort analyses, we investigated the follow-
ing potential risk factors: age, sex, year of start date, ASA
indication (myocardial infarction, unstable angina, ischae-
mic heart disease and cerebrovascular disease), history of
PUD and use of proton pump inhibitors (PPIs). A history
of PUD any time before the start date was defined as any
record of peptic ulcer symptoms, or a diagnosis of uncom-
plicated or complicated PUD. We defined PPI users at
their start date as those who had received at least one pre-
scription for a PPI in the month before or in the week
after their first ASA prescription (start date).For nested case–control analyses, information on co-
morbidities and other potential risk factors, such as
smoking, alcohol use and body mass index (BMI), were
collected from patients’ records at any time before the
index date. We assessed gastroesophageal reflux disease
(GERD) and symptoms related to PUD, including vomit-
ing, nausea, epigastric pain, dyspepsia, heartburn and
gastritis between the start date and the index date. In
addition, data on the number of PCP visits, referrals and
hospitalizations recorded for each patient were collected
for the year before their index date. Finally, for the
case–control analyses, information on patients’ drug ex-
posure was assessed between their start date and index
date, and was categorized as follows: current use, when
the supply of the most recent prescription lasted until
the index date or ended in the 30 days preceding the
index date; past use, when the supply of the most recent
prescription ended 31-365 days before the index date;
and non-use, when the most recent prescription ended
more than 365 days before the index date or there was
no recorded use at any time between the start date and
the index date.
Statistical analysis
The overall incidence of uncomplicated PUD and associ-
ated 95% confidence interval (CI) was determined along
with age- and sex-specific estimates. We also calculated
the incidence of uncomplicated PUD in subgroups of
ASA users with and without a history of PUD before
their start date. The incidence of uncomplicated PUD in
new users of low-dose ASA who were exposed to a PPI
at their start date was also compared with the incidence
in those who were not exposed to a PPI at their start
date. Nelson–Aalen cumulative hazard estimates were
calculated for ASA users with and without a history of
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(HRs) and associated 95% CIs were calculated using Cox
regression analyses adjusted for age, sex, year of start
date, ASA indication, PPI use and history of PUD. All
variables were ascertained at the start date.
Nested case–control analyses were performed to esti-
mate the contribution of various risk factors to the devel-
opment of uncomplicated PUD during follow-up. Odds
ratios (ORs) and associated 95% CIs were calculated by
unconditional multiple logistic regression models. All esti-
mates were adjusted for frequency-matched variables (age,
sex, follow-up time) and for health service utilization (PCP
visits and referrals), smoking, and use of acid-suppressing
drugs, non-steroidal anti-inflammatory drugs (NSAIDs),
ASA and paracetamol.
Statistical analyses were performed using Stata® version
12.0 (StataCorp LP, College Station, TX, USA).
Results
Incidence of uncomplicated PUD
The crude incidence of uncomplicated PUD in new users
of low-dose ASA was 1.41 per 1000 person-years (95% CI,
1.26-1.58). For women and men, the incidences were 1.56
per 1000 person-years (95% CI, 1.33-1.83) and 1.30 per
1000 person-years (95% CI, 1.11-1.52), respectively. When
stratified by age, women aged 50-59 years had a higher in-
cidence of uncomplicated PUD (2.19 per 1000 person-
years, 95% CI, 1.43-3.34) than men in the corresponding
age group (1.16 per 1000 person-years, 95% CI, 0.77-1.76).
For patients aged 80-84, the opposite was observed
(Figure 2). A higher incidence of uncomplicated PUD was
observed in new users of ASA with a history of PUD (3.03
per 1000 person-years, 95% CI, 2.26-4.08) than in those
without such a history (1.30 per 1000 person-years, 95%































Figure 2 Incidence of uncomplicated peptic ulcer disease by
age and sex.analysis, patients with a history of PUD had a significantly
greater probability of developing uncomplicated PUD than
patients without such a history (log-rank test, p < 0.001;
Figure 3). New users of ASA exposed to a PPI at their start
date had a higher incidence of uncomplicated PUD (1.84
per 1000 person-years, 95% CI, 1.45-2.32) than those not
exposed (1.32 per 1000 person-years, 95% CI, 1.16-1.50).
Risk factors for uncomplicated PUD
In an adjusted Cox regression analysis, sex, year of start
date, ASA indication and use of PPIs did not appear to
be associated with an increased risk of uncomplicated
PUD (Table 1). Older patients (aged 80-84 years) were
more likely to develop uncomplicated PUD than patients
aged 50-59 years (adjusted HR, 1.69; 95% CI, 1.05-2.74).
New users of low-dose ASA with a history of PUD were
about twofold more likely to develop uncomplicated
PUD than those without such a history (adjusted HR,
2.22; 95% CI, 1.60-3.09).
In nested case–control analyses, smoking was a pre-
dictor of uncomplicated PUD development (adjusted OR,
1.96; 95% CI, 1.37-2.80) (Table 2). We further examined
the association between smoking and uncomplicated PUD
according to the ulcer site (stomach or duodenum).
Smokers had a threefold greater risk of duodenal ulcer
than non-smokers (adjusted OR, 3.40; 95% CI: 1.94-5.97),
whereas the risk of gastric ulcer was increased by less than
twofold (adjusted OR, 1.64; 95% CI, 1.04-2.59). The risk of
developing uncomplicated PUD was twofold greater for
patients with four or more referrals to a specialist during
the year preceding their index date than for those who
had not been referred (adjusted OR, 1.98; 95% CI, 1.30-
3.00). Individuals living in urban areas were more likely to
experience uncomplicated PUD than those living in rural
areas (adjusted OR, 3.21; 95% CI, 1.46-7.04). Patients
living in the most deprived areas (as measured by the
Townsend deprivation index) had an increased risk of un-
complicated PUD compared with those living in the least
deprived areas (adjusted OR, 1.56; 95% CI, 1.01-2.39).
Alcohol use and BMI did not have a statistically significant
effect on the risk of uncomplicated PUD. Among the co-
morbidities investigated, an increased risk of uncompli-
cated PUD in new users of low-dose ASA was associated
with anaemia (adjusted OR, 2.53; 95% CI, 1.82-3.53), stress
(adjusted OR, 1.58; 95% CI, 1.06-2.33) and depression
(adjusted OR, 1.38; 95% CI, 1.04-1.83). The presence of
uncomplicated PUD symptoms (e.g. nausea, vomiting and
epigastric pain) after initiation of ASA treatment was a
predictor of uncomplicated PUD (adjusted OR, 2.09;
95% CI, 1.56-2.81), whereas a diagnosis of GERD during
follow-up was not (adjusted OR, 1.13; 95% CI, 0.81-1.57).
Overall, current use of NSAIDs (selective cyclooxygenase-
2 [COX-2] inhibitors and traditional NSAIDs) was associ-
ated with a significantly increased risk of uncomplicated















































Figure 3 Nelson–Aalen cumulative hazard estimates for the development of uncomplicated peptic ulcer disease. Abbreviation:
PUD-Peptic ulcer disease.
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considered separately, the association was significant for
COX-2 inhibitors (adjusted OR, 2.33; 95% CI, 1.13-4.79)
but was not for traditional NSAIDs (adjusted OR, 1.36;
95% CI, 0.93-1.99). Current use of oral steroids and
current use of paracetamol were also associated with an
increased risk of PUD (adjusted OR, 1.88; 95% CI, 1.09-
3.25 and adjusted OR, 1.45; 95% CI, 1.08-1.95, respect-
ively) (Table 3). An association between acid-suppressing
drugs and uncomplicated PUD was observed: current
users of PPIs and current users of histamine-2 receptor
antagonists (H2RAs) were significantly more likely to have
uncomplicated PUD than non-users of these drugs (ad-
justed OR, 1.68; 95% CI, 1.26-2.25 and adjusted OR, 2.26;
95% CI, 1.34-3.82, respectively). When current users of
PPI therapy were divided into subgroups, current use of
PPI therapy initiated more than 30 days after the start date
was significantly associated with an increased risk of un-
complicated PUD (adjusted OR, 2.38; 95% CI, 1.65-3.42),
whereas current use of PPI intitiated before the start date
or within the 30 days after the start date was not signifi-
cantly associated (adjusted OR, 1.25; 95% CI, 0.86-1.80).
In a secondary analysis, regression models were com-
puted only for current users of low-dose ASA at the
index date. Estimates of risks for the development of un-
complicated PUD in current low-dose ASA users were
comparable to those observed for the whole cohort for
all variables (Additional file 1: Table S1 and Additional
file 2: Table S2).Discussion
Few epidemiological studies have investigated risk factors
for uncomplicated PUD separately from risk factors for
complicated PUD, particularly in a population of new
users of ASA. The overall incidence of uncomplicated
PUD in this population was 1.41 per 1000 person-years
and was higher than the incidence calculated for the
general population [13,16]. A similar incidence of upper
gastrointestinal bleeding was observed in the same cohort
of new users of ASA (1.12 per 1000 person-years) [3].
Our results indicate that the development of uncompli-
cated PUD in new users of low-dose ASA for the preven-
tion of cardiovascular events was associated with social
deprivation, a history of PUD, smoking, stress, depression,
anaemia and use of NSAIDs, COX-2 inhibitors and oral
steroids. This was in line with the risk factors for uncom-
plicated PUD observed in the general population [4,13,22].
Many of the risk factors for uncomplicated PUD identified
in this study have also been demonstrated to increase the
risk of complications of PUD in the general population;
previous studies have reported an increased risk of upper
gastrointestinal bleeding associated with smoking [23-27],
use of NSAIDs [24,25,27-29], use of COX-2 inhibitors [24]
and use of high doses of oral steroids [24].
Among the risk factors identified in our study, a his-
tory of PUD has been shown by other investigators to
increase the risk of upper gastrointestinal bleeding in
ASA users [3]. The use of drugs such as NSAIDs, COX-
2 inhibitors and oral steroids has also been shown to
Table 1 Hazard ratios for uncomplicated peptic ulcer
disease associated with factors assessed at the start date
(cohort analysis)















Cerebrovascular disease 1 (-)
Myocardial infarction 1.12 (0.82-1.53)
Ischaemic heart disease 1.06 (0.81-1.39)
Unstable angina 1.25 (0.60-2.59)
PPI use at start date
No 1 (-)
Yes 1.23 (0.93-1.62)
History of PUD at start date
No 1 (-)
Yes 2.22 (1.60-3.09)
aHRs estimated by Cox regression analyses and adjusted for all variables in
the table.
Abbreviations: ASA-Acetylsalicylic acid; CI-Confidence interval; HRs-Hazard ratios;
PPI-Proton pump inhibitor; PUD-Peptic ulcer disease.
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users of ASA [3,24]. In a similar population of new ASA
users, patients using NSAIDs were almost three times
more likely to develop upper gastrointestinal bleeding
than non-users of NSAIDs [3]. This is higher than the
observed risk for uncomplicated PUD in the current
study, and may suggest that some cases of PUD remain
undiagnosed until complications occur.
Current use of acid-suppressing therapy (PPIs or
H2RAs) was associated with an increased risk of devel-
oping uncomplicated PUD in new ASA users. A similar
association between the use of PPIs and an increased
risk of PUD recurrence was observed in Finland [30]. In
our study, the association between PPIs and uncompli-
cated PUD was mainly observed for a subgroup of indi-
viduals whose PPI therapy started more than 30 days
after their first ASA prescription. In contrast, no in-
creased risk was observed for individuals whose PPItherapy had been started before or at the same time as
their first ASA prescription. In line with observations from
others [31], this association is likely to be explained by
confounding by indication. PPIs prescribed at some point
after initiating ASA therapy might be a marker of develop-
ing upper gastrointestinal symptoms during ASA therapy
in patients who may be at greater background ulcer risk
than individuals not starting PPI therapy during their
follow-up. Similarly, the increased risk of uncomplicated
PUD observed in current users of H2RAs is likely due to
confounding by indication, whereby H2RAs are prescribed
to treat the symptoms of uncomplicated PUD.
The increased risk of uncomplicated PUD associated
with the use of paracetamol suggests that paracetamol
may potentiate the ulcerogenicity of ASA. This association,
however, remains unclear and may be spurious; patients
with diagnosed uncomplicated PUD may be preferentially
prescribed paracetamol as a safer alternative to NSAIDs.
Among the comorbidities investigated, anaemia was
associated with the highest risk of developing uncompli-
cated PUD. In the absence of overt bleeding, this might
be explained by undiagnosed gastrointestinal micro-
bleeding caused by uncomplicated PUD [15]. The causal
direction of this association, however, remains unclear
and the hypothesis that anaemia might be a predictor of
uncomplicated PUD cannot be ruled out.
The association between Helicobacter pylori infection
and PUD is well established [26,32,33]. In our study, the
incomplete recording of H. pylori infection in definite
cases together with the overall lack of H. pylori status in
the general population, including controls, prevented us
from analysing the role of H. pylori.
The present study has the strength of using a large pri-
mary care database that is representative of the UK
population and has been validated for use in epidemio-
logical studies [17,18]. Additionally, THIN is likely to af-
ford more accurate estimates of uncomplicated PUD
incidence than hospital-based databases [34]. It should
be noted that THIN does not report use of over-the-
counter (OTC) medications. Prescription medications,
however, are free for patients aged 60 years or older in
the UK, and health care is easily accessed, which is likely
to encourage prescription rather than OTC medication
use. In our study, most patients (87.3%) were aged
60 years or older and therefore misclassification of drug
use due to medications being obtained OTC should not
greatly affect our study results.
Another key strength of the study is that potential
cases of uncomplicated PUD were carefully ascertained
by manually reviewing patients’ records, including free-
text comments. Despite this careful process, however,
when PCPs were contacted to confirm the diagnosis of
uncomplicated PUD, the confirmation rate was about
80%. Most of the misclassification was due to cases of
Table 2 Odds ratios for the risk of uncomplicated peptic
ulcer disease associated with patient characteristics and











Male 1046 (52.3) 161 (52.1) NA
Female 954 (47.7) 148 (47.9) NA
Age at index date, years
50-59 250 (12.5) 43 (13.9) NA
60-69 575 (28.7) 86 (27.8) NA
70-79 859 (43.0) 129 (41.7) NA
80-84 316 (15.8) 51 (16.5) NA
Follow-up time, months
< 6 211 (10.5) 38 (12.3) NA
6-12 227 (11.4) 33 (10.7) NA
13-24 335 (16.8) 55 (17.8) NA
25-48 538 (26.9) 80 (25.9) NA
> 48 689 (34.5) 103 (33.3) NA
Visits to PCPb
< 3 62 (3.1) 3 (1.0) 1 (-)
4-9 544 (27.2) 47 (15.2) 1.35 (0.40-4.52)
≥ 10 1394 (69.7) 259 (83.8) 2.03 (0.61-6.76)
Referralsb
0 466 (23.3) 37 (12.0) 1 (-)
1-3 834 (41.7) 118 (38.2) 1.46 (0.97-2.20)
≥ 4 700 (35.0) 154 (49.8) 1.98 (1.30-3.00)
Hospitalizationsb
0 1584 (79.2) 213 (68.9) 1 (-)
≥ 1 416 (20.8) 96 (31.1) 1.21 (0.90-1.63)
Smoking
Non-smoker 800 (40.0) 105 (34.0) 1 (-)
Smoker 267 (13.4) 67 (21.7) 1.96 (1.37-2.80)
Ex-smoker 892 (44.6) 135 (43.7) 1.01 (0.76-1.34)
Unknown 41 (2.1) 2 (0.6) 0.48 (0.11-2.08)
BMI, kg/m2
11-19 67 (3.4) 15 (4.9) 1.11 (0.59-2.11)
20-24 489 (24.4) 86 (27.8) 1 (-)
25-29 781 (39.1) 114 (36.9) 0.81 (0.59-1.11)
≥ 30 510 (25.5) 80 (25.9) 0.83 (0.59-1.18)
Unknown 153 (7.6) 14 (4.5) 0.69 (0.37-1.31)
Table 2 Odds ratios for the risk of uncomplicated peptic
ulcer disease associated with patient characteristics and










Alcohol use, units per week
0 88 (4.4) 19 (6.1) 1 (-)
1-4 377 (18.9) 58 (18.8) 0.67 (0.37-1.21)
5-15 395 (19.8) 56 (18.1) 0.64 (0.35-1.17)
≥ 16 148 (7.4) 22 (7.1) 0.65 (0.31-1.32)
Unknown 992 (49.6) 154 (49.8) 0.66 (0.38-1.16)
Practice location
Rural 235 (6.8) 7 (2.3) 1 (-)
Urban 1382 (69.1) 233 (75.4) 3.21 (1.46-7.04)
Town 240 (12.0) 28 (9.1) 2.38 (1.00-5.68)
Unknown 243 (12.2) 41 (13.3) 2.75 (1.18-6.42)
Townsend deprivation index
1 (least deprived) 489 (24.4) 59 (19.1) 1 (-)
2 435 (21.8) 55 (17.8) 1.09 (0.73-1.63)
3 411 (20.5) 68 (22.0) 1.29 (0.88-1.90)
4 382 (19.1) 68 (22.0) 1.35 (0.91-1.99)
5 (most deprived) 54 (17.5) 54 (17.5) 1.56 (1.01-2.39)




629 (31.5) 91 (29.4) 0.89 (0.68-1.17)
Ischaemic heart
diseasec
1382 (69.1) 221 (71.5) 1.07 (0.81-1.41)
Myocardial infarctionc 514 (25.7) 97 (31.4) 1.26 (0.96-1.66)
Hypertensionc 1223 (61.2) 180 (58.3) 0.82 (0.63-1.06)
Hyperlipidaemiac 697 (34.9) 114 (36.9) 1.08 (0.83-1.41)
Diabetes mellitusc 328 (16.4) 60 (19.4) 1.08 (0.78-1.50)
Goutc 176 (8.8) 22 (7.1) 0.70 (0.43-1.14)
Rheumatoid arthritisc 55 (2.8) 20 (6.5) 1.46 (0.83-2.58)
Osteoarthritisc 858 (42.9) 157 (50.8) 1.13 (0.87-1.46)
COPDc 158 (7.9) 34 (11.0) 1.08 (0.71-1.65)
Asthmac 324 (16.2) 54 (17.5) 0.82 (0.59-1.15)
Anaemiac 177 (8.8) 70 (22.7) 2.53 (1.82-3.53)
Stressc 158 (7.9) 42 (13.6) 1.58 (1.06-2.33)
Anxietyc 351 (17.6) 70 (22.7) 1.21 (0.89-1.64)
Depressionc 474 (23.7) 103 (33.3) 1.38 (1.04-1.83)
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Table 2 Odds ratios for the risk of uncomplicated peptic
ulcer disease associated with patient characteristics and










IBSc 129 (6.5) 25 (8.1) 1.06 (0.66-1.71)
GERDc 280 (14.0) 60 (19.4) 1.13 (0.81-1.57)
Uncomplicated PUD
symptomsd
471 (23.6) 133 (43.0) 2.09 (1.56-2.81)
aOR adjusted for age, sex, follow-up time, health service utilization (PCP visits
and referrals), smoking and drug use during the study period (gastroprotective
drugs, NSAIDs, ASA and paracetamol).
bIn year before the index date.
cDiagnosed before the index date. Relative to being free from the comorbidity.
dDiagnosed between the start date and the index date. Relative to being free
from symptoms.
Abbreviations: ASA-Acetylsalicylic acid; BMI-Body mass index; CI-Confidence
interval; COPD-Chronic obstructive pulmonary disease; GERD-Gastroesophageal
reflux disease; IBS-Irritable bowel syndrome; NA-Not assessed; NSAIDs-Non-
steroidal anti-inflammatory drugs; OR-Odds ratio; PCP-Primary care physician;
PUD-Peptic ulcer disease.
Table 3 Odds ratios for the risk of uncomplicated peptic











NSAIDs 206 (10.3) 57 (18.4) 1.50 (1.06-2.13)
Selective COX-2
inhibitors
28 (1.4) 13 (4.2) 2.33 (1.13-4.79)
tNSAIDs 178 (8.9) 44 (14.2) 1.36 (0.93-1.99)
Paracetamol 492 (24.6) 114 (36.9) 1.45 (1.08-1.95)
Low-dose ASA 1515 (75.8) 245 (79.3) 1.33 (0.87-2.04)
Clopidogrel 157 (7.9) 29 (9.4) 0.94 (0.60-1.48)
Oral anticoagulants 84 (4.2) 8 (2.6) 0.68 (0.31-1.48)
Dipyridamole 62 (3.1) 9 (2.9) 0.78 (0.37-1.62)
PPIs 453 (22.7) 107 (34.6) 1.68 (1.26-2.25)
Used on start dateb 266 (13.3) 48 (15.5) 1.25 (0.86-1.80)
Use initiated after
start datec
187 (9.3) 59 (19.1) 2.38 (1.65-3.42)
H2RAs 60 (3.0) 23 (7.4) 2.26 (1.34-3.82)
Oral steroids 58 (2.9) 21 (6.8) 1.88 (1.09-3.25)
SSRIs 103 (5.2) 27 (8.7) 1.45 (0.91-2.32)
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only reflects symptomatic uncomplicated PUD; in the
absence of endoscopy, asymptomatic uncomplicated PUD
remains undiagnosed.Tricyclic antidepressants 105 (5.3) 19 (6.1) 1.03 (0.61-1.74)
Statins 1431 (71.6) 220 (71.2) 0.89 (0.65-1.23)
aOR adjusted for age, sex, follow-up time, health service utilization (PCP visits
and referrals), smoking and drug use during study period (gastroprotective
drugs, NSAIDs, ASA and paracetamol). Relative to non-use of drug.
bPPI therapy in use on the start date or started within the 30 days after the
start date.
cPPI therapy started after the first 30 days of follow-up.
Abbreviations: ASA-Acetylsalicylic acid; CI-Confidence interval; COX-2-
Cyclooxygenase-2; H2RAs-Histamine-2 receptor antagonists; NSAIDs-Non-steroidal
anti-inflammatory drugs; OR-Odds ratio; PCP-Primary care physician; PPIs-Proton
pump inhibitors; PUD-Peptic ulcer disease; SSRIs-Selective serotonin reuptake
inhibitors; tNSAIDs-Traditional non-steroidal anti-inflammatory drugs.Conclusions
In conclusion, every year, uncomplicated PUD develops in
approximately 1-2 patients per 1000 taking low-dose ASA
for the secondary prevention of cardiovascular events,
adding to the burden of disease associated with compli-
cated PUD in this population. This incidence rises to 3
patients per 1000 in those with a history of PUD. Other
factors that significantly increase the risk of uncompli-
cated PUD in new ASA users include smoking, depres-
sion, anaemia, current use of acid-suppressing drugs and
NSAIDs. Therefore, physicians should closely monitor
ASA users for gastrointestinal symptoms and signs of
ulcers, particularly if they have additional risk factors. This
may allow early diagnosis of uncomplicated PUD and
help to reduce the development of complications.Consent
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